These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 11654438

  • 21. OPRR and FDA propose revised expedited review categories.
    McGough H.
    IRB; 1998; 20(1):9, 11. PubMed ID: 11655326
    [No Abstract] [Full Text] [Related]

  • 22. Continuing review of research involving human subjects: approach to the problem and remaining areas of concern.
    Gordon B, Prentice E.
    IRB; 1997; 19(2):8-11. PubMed ID: 11655323
    [No Abstract] [Full Text] [Related]

  • 23. Federal agency keeps review committee after public comments support continuation.
    Maloney DM.
    Hum Res Rep; 1997 Jan; 12(1):1-2. PubMed ID: 11654603
    [No Abstract] [Full Text] [Related]

  • 24. Two rules on expedited IRB reviews are final.
    Maloney DM.
    Hum Res Rep; 1999 Jan; 14(1):3. PubMed ID: 11657557
    [No Abstract] [Full Text] [Related]

  • 25. Neurobiological research involving human subjects: perspectives from the Office for Protection from Research Risks.
    Puglisi JT, Ellis GB.
    Account Res; 1996 Jan; 4(3-4):261-5. PubMed ID: 11654521
    [No Abstract] [Full Text] [Related]

  • 26. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
    Gordon VM, Sugarman J, Kass N.
    IRB; 1998 Jan; 20(1):1-5. PubMed ID: 11655324
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Review panel cancels meeting as gene therapy proposals fall.
    Wadman M.
    Nature; 1996 Feb 22; 379(6567):668. PubMed ID: 11644770
    [No Abstract] [Full Text] [Related]

  • 33. New policy on research with children is part of trend toward including more research subjects.
    Maloney DM.
    Hum Res Rep; 1998 May 22; 13(5):1-2. PubMed ID: 11657189
    [No Abstract] [Full Text] [Related]

  • 34. IRB review of adverse events in investigational drug studies.
    Prentice ED, Gordon B.
    IRB; 1997 May 22; 19(6):1-4. PubMed ID: 11656910
    [No Abstract] [Full Text] [Related]

  • 35. Testing drugs in pediatric populations: the FDA mandate.
    Tauer CA.
    Account Res; 1999 May 22; 7(1):37-58. PubMed ID: 11657562
    [No Abstract] [Full Text] [Related]

  • 36. An even safer safety net.
    Prentice E.
    Hastings Cent Rep; 1997 May 22; 27(3):46. PubMed ID: 11644996
    [No Abstract] [Full Text] [Related]

  • 37. The noninstitutional review board: a case history.
    Herman SS.
    IRB; 1984 May 22; 6(1):1-3, 12. PubMed ID: 11649540
    [No Abstract] [Full Text] [Related]

  • 38. FDA revises informed consent regulations for emergency research.
    Menasché A, Levine RJ.
    IRB; 1995 May 22; 17(5-6):19-22. PubMed ID: 11653359
    [No Abstract] [Full Text] [Related]

  • 39. IRB jurisdiction and limits on IRB actions.
    Hershey N, Cann CI, Rothman KJ.
    IRB; 1985 May 22; 7(2):7-9. PubMed ID: 11649624
    [No Abstract] [Full Text] [Related]

  • 40. NIH guidelines for research involving recombinant DNA molecules.
    Wilson DJ.
    Account Res; 1993 May 22; 3(2-3):177-85. PubMed ID: 11652293
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.